Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.
Bavarian Nordic – poxviral-based vaccine
Bavarian Nordic has built its foundation around two poxviral-based vaccine platform technologies, Modified Vaccinia Ankara – Bavarian Nordic (MVA-BN) and Vaccinia-Fowlpox-TRICOM (VF-TRICOM) that have the potential to support a broad product pipeline in both infectious diseases and cancer immunotherapies. Both technologies can be manufactured at commercial scale at Bavarian Nordic’s own facility, which was recently expanded to accommodate the production of multiple products. Bavarian Nordic focuses on developing product candidates to address cancer and infectious diseases by leveraging several core strengths:
Extensive R&D expertise in vaccines and immunotherapy
Broadly applicable platform technology
Multiple clinical stage development programs, including two Phase 3 trials
Flexible, commercial scale manufacturing facility
Significant financial resources resulting from IMVAMUNE supply contracts and government-funded R&D programs
Through a long-standing collaboration with the U.S. Government, Bavarian Nordic has developed a portfolio of biological countermeasures, including the non-replicating smallpox vaccine, IMVAMUNE, which is stockpiled for emergency use by the U.S. and other governments. The vaccine is approved in the EU (under the trade name IMVANEX) and in Canada. Bavarian Nordic and its partner Janssen are pioneering the development of an Ebola vaccine, which has been fast-tracked by authorities in response to the current situation in West Africa. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies based on its versatile pox-virus based technologies, including PROSTVAC, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC.
Bavarian Nordic is a biotech company headquartered in Denmark, Germany and USA. Bavarian Nordic’s shares are listed on Nasdaq Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.
ExpreS2ion Biotechnologies is a world leading contract research organization (CRO) for the production in Drosophila Schneider-2 (S2) cells using its proprietary and complete S2 recombinant protein technology ExpreS2.
ExpreS2ion Biotechnologies – production in Drosophila S2 cells
Barentzymes is a biotech company addressing the need for enzyme based solutions in industrial biotechnology and is focused on the development of new original enzymes from the rich genetic resources of the High North.
Immunodiagnostic Systems (IDS) is a biotech company dedicated to the development of innovative immunoassays and automated immunoanalyser technologies for the determination of both 25-Hydroxy Vitamin D and 1,25-Dihydroxy Vitamin D.
Immunodiagnostic systems – Vitamin D determination
ChemoMetec is a biotech company aiming to improve analytical measurement techniques within the fields of particle counting and liquid chemical composition determination. ChemoMetec mainly focus in liquids analysis, especially for use in life sciences research, clinical diagnostics, production and quality control for pharmaceutical industries.
AROS Applied Biotechnology is a leading provider of Total Genomic Solutions in Europe, covering all steps of the process, from study design, extraction, sample banking, analysis to advanced bioinformatics.
AROS Applied Biotechnology – total genomic solutions